The Cooper (The Cooper) ROCE % : 5.51% (As of Jan. 2024)

View and export this data going back to 1983. Start your Free Trial

What is The Cooper ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. The Cooper's annualized ROCE % for the quarter that ended in Jan. 2024 was 5.51%.

The Cooper ROCE % Historical Data

The historical data trend for The Cooper's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Cooper ROCE % Chart

The Cooper Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

ROCE %

Get a 7-Day Free Trial

10.16

5.57

7.05

5.58

4.96

The Cooper Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
ROCE %	Get a 7-Day Free Trial															5.68	3.45	5.47	4.96	5.51

The Cooper ROCE % Calculation

The Cooper's annualized ROCE % for the fiscal year that ended in Oct. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Oct. 2023 )		(A: Oct. 2022 )		(A: Oct. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Oct. 2023 )		(A: Oct. 2022 )		(A: Oct. 2023 )
	=	518.2	/	( ( (11492.3 - 1280.2)	+	(11658.9 - 969) )	/ 2 )
	=	518.2	/	( (10212.1	+	10689.9)	/ 2 )
	=	518.2	/	10451
	=	4.96 %

The Cooper's ROCE % of for the quarter that ended in Jan. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	599.6	/	( ( (11658.9 - 969)	+	(12032.6 - 964.9) )	/ 2 )
	=	599.6	/	( ( 10689.9	+	11067.7 )	/ 2 )
	=	599.6	/	10878.8
	=	5.51 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

The Cooper (NAS:COO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

The Cooper ROCE % Related Terms

Thank you for viewing the detailed overview of The Cooper's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

The Cooper (The Cooper) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Cooper Companies Inc (NAS:COO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

COO:Mexico CP6:Germany C1OO34:Brazil

Address

6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, USA, 94583

Website

https://www.coopercos.com

The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.

Executives

Gary S Petersmeyer	director	3400 CENTRAL AVENUE, SANTA CLARA CA 95051
Robert S Weiss	director, officer: EVP and CFO	6140 STANERIDGE MALL RES #590, PLEASSANTON CA 94503
Agostino Ricupati	officer: Sr. VP, Finance & Tax	C/O THE COOPER COMPANIES, INC., 6140 STONERIDGE MALL ROAD, SUITE 590, PLEASANTON CA 94588
Warner Gerard H Iii	officer: President, CooperVision, Inc.	C/O COOPER COMPANIES INC., 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON CA 94583
Jody S Lindell	director	2536 FILLMORE ST., SAN FRANCISCO CA 94115
Cynthia L Lucchese	director	7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260
Nicholas Khadder	officer: VP, General Counsel & Corp Sec	2836 JOHNSON AVENUE, ALAMEDA CA 94501
Daniel G Mcbride	officer: VP and Senior Counsel	5 EL CORTE, ORINDA CA 94563
Brian G Andrews	officer: Treasurer	4300A 17TH STREET, SAN FRANCISCO CA 94114
Maria Rivas	director	C/O MEDIDATA SOLUTIONS, INC., 350 HUDSON STREET, 9TH FLOOR, NEW YORK NY 10014
White Albert G Iii	officer: VP & Treasurer	6790, SPRINGDALE COURT, VICTOR NY 14564
Teresa S Madden	director	414 NICOLLET MALL, MINNEAPOLIS MN 55401
Robert D Auerbach	officer: President, CSI	C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Holly R Sheffield	officer: EVP, CSO	C/O THE COOPER COMPANIES, INC., 6140 STONERIDGE MALL ROAD, SUITE 590, PLEASANTON CA 94588
Mark J Drury	officer: VP, General Counsel & Sec.	C/O COOPERCOMPANIES, 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON CA 94583